Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

作者：Mahan Charles E^*; Holdsworth Mark T; Welch Shawn M; Borrego Matt; Spyropoulos Alex C

来源：Thrombosis and Haemostasis, 2011, 106(3): 405-415.

DOI：10.1160/TH11-02-0132

• Adverse drug event
• adverse event
• cost model
• deep-vein thrombosis
• preventable

Preventable venous thromboembolism (VIE) and "appropriate" type, dose, and duration of prophylaxis are emerging concepts. Contemporary definitions by key quality organisations, including the World Health Organization, have shifted towards "preventable" VIE being considered an adverse event or adverse drug event. A decision tree and cost model were developed to estimate the United States health care costs for total deep-vein thrombosis (DVT), total hospital-acquired DVT, and total "preventable" DVT. Annual cost ranges were obtained in 2010 US dollars for total ($7.5 to $39.5 billion), hospital-acquired ($5 to $26.5 billion), and preventable ($2.5 to $19.5 billion) DVT costs. When the sensitivity analysis was applied - taking into consideration higher incidence rates and costs - annual US total, hospital-acquired, and "preventable" DVT costs ranged from $9.8 to $52 billion, $6.8 to $36 billion, and $3.4 to $27 billion, respectively.

• 出版日期2011-9